Aurora Cannabis Inc (NYSE: ACB) shares fell in after-hours trading Tuesday after the Canadian cannabis company reported much deeper losses on a year-over-year basis — as well as much higher net sales of CA$65.145 million ($48.4 million) versus $16.1 million in sales in the third quarter of 2018.
The Q3 Print
Aurora said it lost CA$158.35 million in the first quarter, down from the second-quarter loss of CA$237.75 million but up 724 percent from its CA$19.2-million loss one year ago.
Its adjusted EBITDA loss fell from CA$45.52 million in the second quarter to CA$46.6 million. Aurora's adjusted EBITDA loss in the third quarter of 2018 was CA$12.9 million.
Aurora is "well-positioned" for positive EBITDA in the fourth quarter on the back of sustained revenue growth and lower cash costs per gram, the company said.
Cannabis production volume increased by 1,200 percent year-over-year and by 99 percent quarter over-quarter to 15,590 kg.
"The increase in production accelerated through the quarter, with the majority of the harvested volume realized in the last half of the quarter," according to the Edmonton, Alberta-based cannabis producer.
The cash cost to produce per gram fell by 26 percent from the second quarter to CA$1.42 per gram, which Aurora attributed to the initial impact from the scale and efficiency of its Sky growing facility.
View more earnings on ACB
Aurora said that — having completed a $345-million convertible note offering in January —accounting standards mandate a mark-to-market adjustment at the period's end for the derivative portion of the notes.
Due to the increase in the company's stock price since the notes were issued, Aurora said it recorded a $102-million non-cash fair value loss in its third-quarter statement.
Price Action
Aurora shares were down 2.15 percent at $8.20 in after-hours trading Tuesday.
Related Links:
The Week In Cannabis: A&F Tries CBD, GW Pharma Soars On Results, Denver Decriminalizes Mushrooms
Aurora Cannabis Reports Extension Of Exclusive Supply Relationship With Luxembourg
Photo courtesy of Aurora Cannabis.
See more from Benzinga
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.